Dalpiciclib

Small molecule

Also known as SHR6390

Approvedregulatory verdict

Evidence outlook

Approved: In combination with an aromatase inhibitor as initial therapy, HR-positive/HER2-negative... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (2)
CN
  • In combination with an aromatase inhibitor as initial therapy, HR-positive/HER2-negative locally advanced or metastatic breast cancer (Ai Rui Kang, dalpiciclib isethionate tablets)hengrui.com
  • In combination with fulvestrant, HR-positive/HER2-negative breast cancer with disease progression after endocrine therapy (brand Ai Rui Kang, dalpiciclib isethionate tablets, MAH Jiangsu Hengrui)baipharm.chemlinked.com
Product first approved 2021

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
HR+/HER2- Metastatic Breast Cancer
NCT07432178 · Fudan University
2026-04-03 – 2034-03-31 · Breast Cancer
What this study did
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
NCT07354022 · Shandong Suncadia Medicine Co., Ltd.
2026-05-05 – 2031-12 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06612814 · Zhimin Shao
2024-09-01 – 2028-04-30 · Breast Cancer Metastatic
What this study did
NCT05861830 · Peking Union Medical College Hospital
2023-05-15 – 2026-06-30 · Advanced Breast Cancer
What this study did
NCT03966898 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-19 – 2023-12-30 · Advanced Breast Cancer
What this study did
NCT03927456 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-13 – 2022-12-30 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT04842617 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-30 – 2031-10-31 · Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06009627 · Tianjin Medical University Cancer Institute and Hospital
2023-04-11 – 2025-09-11 · Breast Cancer
What this study did
Phase 2 (61)
HR+/HER2- Metastatic Breast Cancer
NCT07935226 · Harbin Medical University
2026-12-15 – 2032-06-30 · Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07014410 · Zhejiang Cancer Hospital
2023-02-01 – 2029-12-31 · Breast Cancer
What this study did
NCT07539753 · Nanfang Hospital, Southern Medical University
2026-06-01 – 2029-08-01 · Breast Cancer, Brain Metastases, HR+/HER2- Breast Cancer
What this study did
NCT06556862 · Beijing 302 Hospital
2025-10-01 – 2028-12-31 · HR+/HER2- Advanced Breast Cancer
What this study did
NCT07285382 · wanghaibo
2025-06-25 – 2028-12-31 · HR Positive HER2 Negative Advanced Breast Cancer
What this study did
NCT07810088 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-28 – 2028-12-01 · HR+ / HER2- Advanced Breast Cancer
What this study did
NCT05949541 · Fudan University
2023-07-26 – 2028-01 · Breast Cancer, Advanced Breast Cancer
What this study did
NCT05431504 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-06 – 2027-12 · Advanced Breast Cancer
What this study did
NCT05759572 · Fudan University
2023-03-01 – 2027-07-01 · Breast Cancer Metastatic
What this study did
NCT05759546 · Fudan University
2023-02-01 – 2027-06-01 · Breast Cancer Metastatic
What this study did
NCT05463601 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-08-01 – 2026-12-31 · Metastatic Breast Cancer
What this study did
NCT06495515 · Tianjin Medical University Cancer Institute and Hospital
2024-08-01 – 2026-12-30 · CANCER, BRAEST CANCER, Late Frontline
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT06149130 · Tongji Hospital
2024-01-11 – 2026-11-30 · Breast Cancer
What this study did
NCT05205200 · Fudan University
2022-06-06 – 2026-08-01 · Breast Cancer, Metastatic Cancer
What this study did
NCT05577923 · Fudan University
2022-11-01 – 2026-03-01 · Metastatic Breast Cancer
What this study did
NCT05806671 · Tianjin Medical University Cancer Institute and Hospital
2023-05 – 2025-12 · Breast Cancer
What this study did
NCT06133088 · Zhejiang Cancer Hospital
2023-08-01 – 2025-08-31 · Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
What this study did
NCT05800756 · Yantai Yuhuangding Hospital
2022-08-04 – 2025-07-30 · Breast Cancer
What this study did
NCT06243185 · Fengzhi Feng
2023-11-17 – 2025-06-30 · Recurrent Ovarian Carcinoma
What this study did
NCT04355858 · Fudan University
2020-05-01 – 2025-04-01 · Breast Cancer, Metastatic Cancer
What this study did
NCT04997798 · First Affiliated Hospital of Zhejiang University
2022-09-01 – 2024-12 · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
What this study did
NCT05577442 · Peking University Cancer Hospital & Institute
2022-10-20 – 2024-10-20 · Breast Neoplasm Female
What this study did
NCT05469750 · Fujian Medical University Union Hospital
2022-08-10 – 2024-08 · Advanced Breast Cancer
What this study did
NCT04733417 · Tianjin Medical University Cancer Institute and Hospital
2021-05-26 – 2023-09-30 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04836520 · Tianjin Medical University Cancer Institute and Hospital
2021-08-02 – 2023-03-31 · Breast Cancer
What this study did
Other / comorbidity
NCT07581834 · Fujian Cancer Hospital
2026-01-21 – 2032-06-30 · Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT07101159 · Fujian Cancer Hospital
2025-09 – 2031-12 · Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
What this study did
NCT06970912 · Peking University People's Hospital
2025-08-01 – 2029-12-31 · Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer, ctDNA Monitoring, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT07610720 · Sun Yat-sen University
2026-06-01 – 2029-11-01 · Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
What this study did
NCT07815522 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-10-01 – 2029-10-01 · Salivary Gland Carcinoma
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT06341894 · The First Affiliated Hospital with Nanjing Medical University
2023-11-17 – 2029-06 · Early Breast Cancer
What this study did
NCT07618923 · Tang-Du Hospital
2026-06 – 2029-01 · Breast Cancer, HR Positive/HER2 Low Breast Cancer
What this study did
NCT06107673 · Hebei Medical University Fourth Hospital
2023-09-30 – 2028-12-01 · Breast Cancer
What this study did
NCT07778732 · Tianjin Medical University Cancer Institute and Hospital
2026-09-01 – 2028-09-01 · HNSCC
What this study did
NCT06650748 · Peking University
2025-05-01 – 2028-04-01 · Breast Cancer, Early-stage Breast Cancer
What this study did
NCT05328440 · Henan Cancer Hospital
2022-05-20 – 2028-01-01 · Breast Neoplasms
What this study did
NCT05228951 · Shengjing Hospital
2022-02-10 – 2027-12-31 · Breast Cancer
What this study did
NCT06684600 · Peking University
2024-11-01 – 2027-10-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07238881 · Sun Yat-sen University
2025-11-05 – 2027-06-01 · Hepatocellulcar Carcinoma
What this study did
NCT06552858 · Fudan University
2024-09-01 – 2027-01-31 · Ovarian Cancer
What this study did
NCT06199271 · Zhongzheng Xiang
2024-01-31 – 2026-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06363734 · Tianjin Medical University Cancer Institute and Hospital
2024-04-09 – 2026-12-31 · Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation
What this study did
NCT04486911 · Shengjing Hospital
2020-07-27 – 2026-12-30 · Breast Cancer
What this study did
NCT05952128 · Sun Yat-sen University
2023-07-01 – 2025-12-01 · Sarcoma
What this study did
NCT05721443 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2022-12-01 – 2025-11-01 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
Phase 1/2 (9)
HR+/HER2- Metastatic Breast Cancer
NCT07189884 · The First Affiliated Hospital of Xiamen University
2025-09-23 – 2028-12-31 · Locally Advanced Breast Cancer (LABC)
What this study did
NCT06167694 · Shandong Suncadia Medicine Co., Ltd.
2023-12-20 – 2026-06 · Unresectable or Metastatic Breast Cancer
What this study did
NCT03772353 · Fudan University
2019-05-12 – 2025-12-10 · Breast Cancer
What this study did
NCT05792410 · Jiangsu HengRui Medicine Co., Ltd.
2023-04 – 2025-02-27 · HER2 Low Advanced or Metastatic Breast Cancer
What this study did
NCT05574881 · Fudan University
2022-09-01 – 2025-01-01 · Breast Cancer
What this study did
NCT05176080 · Henan Cancer Hospital
2021-12-08 – 2024-07-03 · Metastatic Breast Cancer
What this study did
NCT03481998 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-22 – 2022-07-30 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT03601598 · Harbin Medical University
2018-07-30 – 2020-07-30 · CRC, HCC, NSCLC
What this study did
Phase 1 (20)
HR+/HER2- Metastatic Breast Cancer
NCT04993430 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2021-10-26 – 2026-12-30 · ER-Positive, HER2-Negative Breast Cancer
What this study did
NCT05586841 · Beijing 302 Hospital
2022-10-01 – 2026-03-30 · HR+/HER2- Advanced Breast Cancer
What this study did
NCT05515289 · Jiangsu HengRui Medicine Co., Ltd.
2022-12-18 – 2023-09-28 · Breast Cancer
What this study did
NCT05103826 · Jiangsu HengRui Medicine Co., Ltd.
2021-10-25 – 2023-06-15 · ER+ / HER2- Advanced Breast Cancer
What this study did
Other / comorbidity
NCT07652762 · Capital Medical University
2026-08-31 – 2029-08 · Meningioma, CDK4/6 Inhibitor
What this study did
NCT06099990 · Jiangsu HengRui Medicine Co., Ltd.
2023-10 – 2028-12 · High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
What this study did
NCT06109207 · West China Hospital
2023-10-31 – 2025-10-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06225921 · West China Hospital
2023-12-29 – 2025-01-15 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04989829 · Jiangsu HengRui Medicine Co., Ltd.
2021-12-27 – 2022-02-14 · Advanced Solid Tumor
What this study did
NCT04973020 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-01 – 2021-10-28 · Advanced Solid Tumor
What this study did
NCT04616742 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-11 – 2021-05-01 · Healthy Adult Male Volunteers
What this study did
NCT04631575 · Jiangsu HengRui Medicine Co., Ltd.
2020-12 – 2021-03 · Hepatic Impairment, Healthy Participants
What this study did
NCT04423601 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-10 – 2021-02-02 · Healthy Subjects
What this study did
NCT04667156 · Jiangsu HengRui Medicine Co., Ltd.
2020-12-13 – 2021-01-29 · Healthy Volunteers
What this study did
NCT04439578 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-23 – 2021-01-15 · Healthy Subjects
What this study did
NCT04301804 · Atridia Pty Ltd.
2020-03-12 – 2020-09-28 · Healthy Volunteers
What this study did
NCT03480256 · Peking University
2018-07-27 – 2020-08 · Gastric Cancer
What this study did
NCT05354336 · The Affiliated Hospital of Qingdao University
2019-06-13 – 2019-08-24 · Healthy Volunteers
What this study did
NCT02684266 · Jiangsu HengRui Medicine Co., Ltd.
2016-03-03 – 2019-06-28 · Neoplasm
What this study did
NCT02671513 · Jiangsu HengRui Medicine Co., Ltd.
2016-01 – 2017-04 · Melanoma
What this study did
Phase 4 (1)
Other / comorbidity
NCT06613373 · Jiangsu Famous Medical Technology Co., Ltd.
2024-10-15 – 2026-10-30 · Breast Cancer
What this study did
Early phase / not applicable (5)
HR+/HER2- Metastatic Breast Cancer
NCT07706933 · Henan Cancer Hospital
2026-11-01 – 2033-06-30 · Breast Cancer
What this study did
NCT06711094 · Fujian Medical University
2025-01-01 – 2028-12-30 · HR+/HER2- Advanced Breast Cancer
What this study did
Other / comorbidity
NCT05132790 · Shengjing Hospital
2023-09-25 – 2028-12-31 · Breast Cancer
What this study did
NCT06810492 · Hongmei Zheng, PhD
2025-04-01 – 2027-12-01 · Breast Cancer Stage III, Breast Cancer Stage II
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT07492394 · Hebei Medical University Fourth Hospital
2025-09-12 – 2031-12-31 · Breast Cancer
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dalpiciclib: this drugPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
ZovegalisibPhase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
SPH4336Phase 2/3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
EvexomostatPhase 2Small moleculeMethionine aminopeptidase 2 (MetAP2, inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 40 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dalpiciclib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
December 2026 (6)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT06107673 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT04993430 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06199271 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06556862 · CT.gov ↗
What to watch
Phase 2Hepatocellulcar CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07238881 · CT.gov ↗
What to watch
2027 (10)
February 2027 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Early Breast CancerRecruiting
Est. primary completion 2027-06 · NCT06341894 · CT.gov ↗
What to watch
Phase 2HNSCCNot yet recruiting
Est. primary completion 2027-06-01 · NCT07778732 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Breast Cancer, Early-stage Breast CancerEnrolling by invitation
Est. primary completion 2027-10-01 · NCT06650748 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-30 · NCT06612814 · CT.gov ↗
What to watch
December 2027 (5)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT06711094 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07285382 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (9)
January 2028 (1)
Phase 2Breast NeoplasmsActive not recruiting
Est. primary completion 2028-01-01 · NCT05328440 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Breast Cancer, HR Positive/HER2 Low Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07618923 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-28 · NCT07810088 · CT.gov ↗
What to watch
Early phase / not applicableBreast CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07706933 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Meningioma, CDK4/6 InhibitorRecruiting
Est. primary completion 2028-08 · NCT07652762 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Salivary Gland CarcinomaRecruiting
Est. primary completion 2028-10-01 · NCT07815522 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Not yet recruiting
Est. primary completion 2028-12 · NCT06099990 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07354022 · CT.gov ↗
What to watch
2029 (3)
May 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-31 · NCT07207070 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT07539753 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer, ctDNA Monitoring …Recruiting
Est. primary completion 2029-12-31 · NCT06970912 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Phase 2HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07892274 · CT.gov ↗
What to watch
2031 (5)
March 2031 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-03-31 · NCT07432178 · CT.gov ↗
What to watch
December 2031 (4)
Phase 2Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07101159 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-12-15 · NCT07935226 · CT.gov ↗
What to watch
Phase 2Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07467330 · CT.gov ↗
What to watch

See the full readout calendar ↗